{"product_id":"aqst-ansoff-analysis","title":"(AQST) Aquestive Therapeutics, Inc. ANSOFF Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGo Beyond the Preview—Access the Full Ansoff Matrix Analysis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Aquestive Therapeutics, Inc. Ansoff Matrix Analysis summarizes growth options across market penetration, market development, product development, and diversification and shows how each quadrant applies to Aquestive’s product pipeline and markets. The page includes a real preview\/sample of the analysis so you can judge style and depth before buying; purchase the full version to receive the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Penetration\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSympazan LGS share\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSympazan, Aquestive Therapeutics, Inc.’s clobazam oral film for Lennox-Gastaut syndrome, supports market penetration by growing use inside the same refractory-epilepsy segment. The film format can help keep specialist prescribing, since about 1 in 10 people with epilepsy have LGS and many need long-term benzodiazepine therapy. That makes share gains depend on deeper uptake, not new indication growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSuboxone MAT share\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSuboxone MAT share is a market penetration play: Suboxone is a buprenorphine\/naloxone sublingual film used in opioid dependence treatment, and it fits the existing medication-assisted treatment setting. Its five marketed strengths, from 2 mg\/0.5 mg to 16 mg\/4 mg, support routine dose titration in clinics and addiction-care programs. For Aquestive Therapeutics, Inc., the aim is to win more prescriptions in a mature, already defined care channel.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZuplenz antiemetic share\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZuplenz is Aquestive Therapeutics, Inc.’s oral soluble ondansetron film for chemotherapy-related and postoperative nausea and vomiting, so its market penetration case is deeper use in the same supportive-care niche. CINV affects up to 70% to 80% of patients without prophylaxis, and PONV hits about 20% to 30% of surgical patients, leaving a clear repeat-prescribing pool. \u003c\/p\u003e\n\u003cp\u003eBecause Zuplenz is already positioned in oncology and post-op care, the growth lever is share gain versus tablets and injectable antiemetics, not a new market. Its value rises if prescribers favor a non-swallow option for patients who vomit or cannot keep pills down. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAzstarys ADHD share\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAzstarys can grow through market penetration by taking more share in the existing ADHD market, not by changing the market itself. Its once-daily dosing is the main hook: in pivotal studies, it showed symptom control through 13 hours, which matters for school and after-school coverage in a market where adherence often drops with multiple daily doses.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOnce-daily use is the core message.\u003c\/li\u003e\n\u003cli\u003eFocus on adherence, not new patients.\u003c\/li\u003e\n\u003cli\u003eLong coverage supports share gains.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eFilm platform reinforcement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAs of fiscal 2025, Aquestive Therapeutics, Inc. still anchored its commercial portfolio on oral soluble and sublingual films, so market penetration comes from pushing the same delivery platform across current brands. That shared format can lift prescriber familiarity and repeat use, which matters in niche neurology and allergy markets.\u003c\/p\u003e\n\u003cp\u003eIt also lowers the sell story: one film platform, multiple branded uses. That helps reinforce recognition without needing a new route of administration.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSame film platform across brands\u003c\/li\u003e\n\u003cli\u003eHigher prescriber familiarity\u003c\/li\u003e\n\u003cli\u003eStronger brand recognition\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGrowth Comes From Deeper Share in Niche Channels, Not New Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMarket penetration for Aquestive Therapeutics, Inc. is about taking more share in the same small, specialist channels for Sympazan, Suboxone MAT, Zuplenz, and Azstarys. The lever is repeat prescribing, dose convenience, and format preference, not new markets.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eBrand\u003c\/th\u003e\n\u003cth\u003ePenetration lever\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSympazan\u003c\/td\u003e\n\u003ctd\u003eLGS share gains\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSuboxone MAT\u003c\/td\u003e\n\u003ctd\u003eMature MAT use\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eZuplenz\u003c\/td\u003e\n\u003ctd\u003eSame-care reuse\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAzstarys\u003c\/td\u003e\n\u003ctd\u003eOnce-daily adherence\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a clear Ansoff Matrix framework for analyzing Aquestive Therapeutics, Inc.’s growth strategy across existing and new products and markets\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a clear Ansoff Matrix for Aquestive Therapeutics to quickly map growth options and reduce strategic planning friction.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eLists vetted regulatory filings, product pipelines, market reports, and investor materials to quickly validate Ansoff growth assumptions for Aquestive Therapeutics.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational film rollout\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAquestive Therapeutics, Inc. can use market development by taking its existing film products into new geographies beyond the U.S., since it already serves both U.S. and international markets. This is the same portfolio, just sold into more countries, so the main lift is registration, local pricing, and distribution. In FY2025, the key question is how much of current film revenue can be extended abroad without heavy new R\u0026amp;D spend.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSympazan geography expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSympazan already has U.S. sales as a clobazam oral film, so geography expansion means taking Lennox-Gastaut syndrome treatment into new country markets. That fits a rare epilepsy niche, where specialist neurologists drive most prescribing and patient counts stay small but persistent. Lennox-Gastaut syndrome is one of the most severe childhood epilepsies and affects about 1 to 2 per 100,000 people. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSuboxone geography expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSuboxone, a buprenorphine\/naloxone sublingual film, is used for opioid dependence, and market development means taking that proven dose form into new national treatment systems. In 2023, U.S. drug overdose deaths were 107,543, with opioids involved in about 76% of cases, showing why access gaps still matter. Expanding abroad can tap a global opioid-use-disorder market that needs easier, lower-friction care.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eZuplenz hospital expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eZuplenz can expand beyond its current use in nausea and vomiting for oncology and post-operative care by winning more hospital formularies and oncology clinics, a clear market development play for Aquestive Therapeutics, Inc. Supportive care is a large need: cancer burden keeps rising, with the World Health Organization projecting about 35 million new cancer cases in 2050, up from 20 million in 2022.\u003c\/p\u003e\n\u003cp\u003eThat makes hospital access, protocol adoption, and physician familiarity the key sales levers.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTarget more hospitals and cancer centers\u003c\/li\u003e\n\u003cli\u003eGrow in supportive-care treatment paths\u003c\/li\u003e\n\u003cli\u003eUse existing clinical need to expand use\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAzstarys market expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAzstarys market development means pushing a once-daily ADHD option into more patient groups and care settings, not just core pediatrics. ADHD affects about 7.1 million U.S. children ages 3 to 17 and 15.5 million U.S. adults, so the addressable market is broad. Its once-daily profile can fit school, home, and adult work-day prescribing.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eExpand beyond core pediatric use\u003c\/li\u003e\n\u003cli\u003eTarget adult and mixed-care settings\u003c\/li\u003e\n\u003cli\u003eFit simpler once-daily prescribing\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAquestive Expands Market Reach Across Key Products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAquestive Therapeutics, Inc. market development means selling the same films in more countries and care settings, with the main work in approvals, pricing, and distribution. Sympazan and Suboxone fit this best because they already prove demand in epilepsy and opioid-use-disorder care. Zuplenz and Azstarys can expand by winning more hospitals, clinics, and adult-prescribing settings.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eMove\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSympazan\u003c\/td\u003e\n\u003ctd\u003eNew geographies\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSuboxone\u003c\/td\u003e\n\u003ctd\u003eNew national systems\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eZuplenz\u003c\/td\u003e\n\u003ctd\u003eMore hospitals\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAzstarys\u003c\/td\u003e\n\u003ctd\u003eMore care settings\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eAquestive Therapeutics, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis is the actual Ansoff Matrix analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full report you'll get, showing real strategic options for Aquestive Therapeutics across market penetration, product development, market development, and diversification.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eProduct Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLibervant seizure rescue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLibervant, a buccal soluble film of diazepam, extends Aquestive Therapeutics into seizure rescue with a new non-oral format for acute use. The product targets an existing seizure-care market, so this is Ansoff product development, not market creation. If approved and adopted, it could diversify revenue beyond Anaphylm and add a second branded CNS asset.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExservan ALS\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eExservan is Aquestive Therapeutics, Inc.'s oral soluble film of riluzole for amyotrophic lateral sclerosis, so in Ansoff terms it is product development: a new dosage form for an existing neurodegenerative disease market. ALS affects about 30,000 people in the United States and adds roughly 5,000 new cases a year, which supports the size of the target base. The film format can help patients who have swallowing trouble, a common ALS issue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAQST-108 systemic epinephrine\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAQST-108 is a sublingual film for systemic epinephrine, and its move beyond anaphylaxis widens Aquestive Therapeutics, Inc.’s pipeline into a new use case and delivery route. That is a product development move, not just a line extension, because it targets a different clinical setting with faster, needle-free dosing. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAQST-305 acromegaly\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAQST-305 is Aquestive Therapeutics, Inc.’s sublingual film of octreotide, built for acromegaly, a rare endocrine disorder with a long-term drug market that is still led by injectable somatostatin analogs. As a new product, it fits Ansoff’s product development path: a new dosage form for an existing therapeutic area, aiming to reduce injection burden and improve use. The move targets a niche market where even modest uptake can matter.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOctreotide, sublingual film\u003c\/li\u003e\n\u003cli\u003eAcromegaly, rare endocrine market\u003c\/li\u003e\n\u003cli\u003eNew product, not a new market\u003c\/li\u003e\n\u003cli\u003eInjection-free delivery angle\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAQST-109 oral epinephrine\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAQST-109 is Aquestive Therapeutics, Inc.'s oral epinephrine candidate for emergency treatment of severe allergic reactions, including anaphylaxis, aimed at a new form factor in the allergy rescue market. It fits Product Development in the Ansoff Matrix because it targets the same acute-use need with a new delivery route, which could expand access beyond injectables. If it wins approval, it could address a market where epinephrine autoinjectors remain the standard of care.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOral epinephrine candidate\u003c\/li\u003e\n\u003cli\u003eTargets anaphylaxis emergencies\u003c\/li\u003e\n\u003cli\u003eNew delivery route, same need\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAquestive’s Drug-Delivery Makeover Targets Familiar Therapies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAquestive Therapeutics, Inc. uses product development to reformat known drugs for the same care setting: diazepam for seizures, riluzole for ALS, epinephrine for anaphylaxis, and octreotide for acromegaly. These are not new markets; they are new delivery forms aimed at easier use, faster dosing, and less injection burden.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCandidate\u003c\/th\u003e\n\u003cth\u003eUse\u003c\/th\u003e\n\u003cth\u003eMatrix fit\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLibervant\u003c\/td\u003e\n\u003ctd\u003eSeizure rescue\u003c\/td\u003e\n\u003ctd\u003eProduct development\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExservan\u003c\/td\u003e\n\u003ctd\u003eALS\u003c\/td\u003e\n\u003ctd\u003eProduct development\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAQST-108\u003c\/td\u003e\n\u003ctd\u003eEpinephrine\u003c\/td\u003e\n\u003ctd\u003eProduct development\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAQST-305\u003c\/td\u003e\n\u003ctd\u003eAcromegaly\u003c\/td\u003e\n\u003ctd\u003eProduct development\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDiversification\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAQST-109 severe allergy market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAQST-109 moves Aquestive Therapeutics into the severe allergy market with an oral epinephrine product, a clear diversification from its current commercialized film brands. This opens a new acute-care use case, where the U.S. sees about 200,000 epinephrine-treated anaphylaxis events each year and food allergies affect roughly 33 million people. If approved, it could widen revenue beyond chronic CNS and GI film products.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAQST-108 epinephrine expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAQST-108 expands Aquestive Therapeutics, Inc. beyond anaphylaxis into systemic epinephrine for other uses, so it is clear diversification in the Ansoff Matrix. This widens the epinephrine franchise from a single emergency setting to a broader therapeutic lane, opening new demand pools. It also lowers reliance on one use case and could build on the same delivery platform.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAQST-305 endocrine entry\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAQST-305 is a clear diversification move for Aquestive Therapeutics, Inc.: an octreotide film for acromegaly, pushing the company into the endocrine specialty market. Acromegaly affects about 40 to 70 people per million, so the target market is niche but high value. It also sits outside Aquestive Therapeutics, Inc.'s current commercialized product set, raising mix and execution risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eExservan rare neurology entry\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eExservan extends Aquestive Therapeutics, Inc. beyond epilepsy by targeting amyotrophic lateral sclerosis, a rare neurology market affecting about 30,000 people in the United States. The riluzole film format is a distinct entry point that broadens the non-epilepsy pipeline and can support niche, high-unmet-need positioning.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eALS-focused rare-neurology expansion\u003c\/li\u003e\n\u003cli\u003eRiluzole oral film platform\u003c\/li\u003e\n\u003cli\u003eNon-epilepsy pipeline breadth\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eKYNMOBI Parkinson's precedent\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEenzymatic? Actually correct: Aquestive helped develop KYNMOBI, approved by the FDA in 2020 for episodic off periods in Parkinson’s disease. That gave the film platform a real proof point outside allergy and pain, in a market where Parkinson’s affects about 1 million Americans and 10 million people worldwide.\u003c\/p\u003e\n\u003cp\u003eThis lowers diversification risk because the same delivery tech has already worked in specialty neurology, not just in one use case. It supports a move into more CNS and movement-disorder assets, where fast onset and non-oral dosing can matter.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFDA approval in 2020\u003c\/li\u003e\n\u003cli\u003eParkinson’s: 1 million U.S.\u003c\/li\u003e\n\u003cli\u003eParkinson’s: 10 million global\u003c\/li\u003e\n\u003cli\u003eProof in specialty neurology\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAquestive Expands Its Film Platform Beyond Allergy and Epilepsy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAquestive Therapeutics, Inc. uses diversification to push its film platform into new markets: AQST-109 and AQST-108 in systemic epinephrine, AQST-305 in acromegaly, and Exservan in ALS. KYNMOBI already proved the delivery tech in Parkinson’s, so the platform is not limited to allergy or epilepsy. This spreads revenue risk across rare, specialty, and acute-care niches.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eNew market\u003c\/th\u003e\n\u003cth\u003eSignal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAQST-109\u003c\/td\u003e\n\u003ctd\u003eAnaphylaxis\u003c\/td\u003e\n\u003ctd\u003eAcute-care entry\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAQST-305\u003c\/td\u003e\n\u003ctd\u003eAcromegaly\u003c\/td\u003e\n\u003ctd\u003eEndocrine expansion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKYNMOBI\u003c\/td\u003e\n\u003ctd\u003eParkinson’s\u003c\/td\u003e\n\u003ctd\u003ePlatform proof\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57233969971465,"sku":"aqst-ansoff-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/aqst-ansoff-matrix.webp?v=1785711251","url":"https:\/\/dcfanalyst.com\/products\/aqst-ansoff-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}